Advertisement
UK markets open in 49 minutes

  • NIKKEI 225

    37,124.80
    -954.90 (-2.51%)
     

  • HANG SENG

    16,144.10
    -241.77 (-1.48%)
     

  • CRUDE OIL

    84.44
    +1.71 (+2.07%)
     

  • GOLD FUTURES

    2,394.40
    -3.60 (-0.15%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    49,930.64
    +661.78 (+1.34%)
     

  • CMC Crypto 200

    1,284.29
    -28.34 (-2.12%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

AstraZeneca boosts lung drug business with up to $2.1 bln Almirall deal

Reuters - UK Focus

LONDON, July 30 (Reuters) - AstraZeneca (NYSE: AZN - news) took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

The British drugmaker, which resisted a $118 billion takeover attempt by Pfizer (NYSE: PFE - news) in May, said it would pay an initial $875 million and up to $1.22 billion in development, launch and sales-related milestones for access to Almirall's existing and pipeline respiratory drugs. (Reporting by Ben Hirschler; editing by Keith Weir)